Antibe Therapeutics Inc.
ATE
Peringkat dalam Saham
#31894
Antibe Therapeutics Inc. is a biotechnology company specializing in the... Antibe Therapeutics Inc. is a biotechnology company specializing in the development of groundbreaking therapeutics and medical devices. Operating internationally, including Canada, Europe, and the United States, their work targets pain, inflammation, and regenerative medicine. A key focus is developing drugs designed to prevent the gastrointestinal harm and bleeding often caused by non-steroidal anti-inflammatory drugs. Their leading candidate, Otenaproxesul, is a hydrogen sulfide-releasing derivative of naproxen. This compound has already finished a Phase 2B gastrointestinal safety study and is being investigated for a range of indications, such as post-operative pain, migraines, dysmenorrhea, traumatic injuries, dental pain, and gout. Additionally, their product portfolio features ATB-352, currently in preclinical development for managing acute pain. The company, incorporated in 2009, is headquartered in Toronto, Canada.
Harga Saham
$0.21483059
Terakhir disinkronkan: 2024-05-07
Kapitalisasi Pasar
$11.13M
Perubahan (1 hari)
0.34%
Perubahan (1 tahun)
-0.36%
Negara
CA
Perdagangan Antibe Therapeutics Inc. (ATE)
Kategori
Healthcare
Rasio P/B untuk Antibe Therapeutics Inc. (ATE)
Rasio P/B per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Antibe Therapeutics Inc., rasio P/B saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/B perusahaan adalah 0.
Riwayat rasio P/B untuk Antibe Therapeutics Inc. dari 2026 hingga 2026
Rasio P/B pada akhir setiap tahun
| Tahun | Rasio P/B | Mengubah |
|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | ||
Rasio P/B untuk perusahaan sejenis atau pesaing
| Perusahaan | Rasio P/B | Perbedaan Rasio P/B | Negara |
|---|---|---|---|
| 3.5116 | - |
US
|
|
| 2.0146 | - |
IE
|
|
| 4.5025 | - |
US
|
|
| 2.5486 | - |
US
|
|
| - | - |
DE
|
